- Conditions
- Bipolar I Disorder, Bipolar II Disorder, Schizo Affective Disorder, Obesity, Weight Loss, GLP - 1
- Interventions
- Group Therapy Program, semaglutide, Phentermine-Topiramate, naltrexone and bupropion (combination)
- Behavioral · Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 125
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Type 2 Diabetes
- Interventions
- Cycloset
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 30 Years to 69 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Type 2 Diabetes
- Interventions
- Tirzepatide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 475 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 5
- States / cities
- Fresno, California • New Port Richey, Florida • Nashua, New Hampshire + 2 more
- Conditions
- CABG
- Interventions
- Placebo, GLP-1 (7-36) amide
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Pre-diabetes, Type 2 Diabetes
- Interventions
- Exenatide, Sitagliptin, Glimepiride
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 3
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Obesity/Therapy
- Interventions
- Semaglutide 1.7mg subcutaneous, Placebo
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 12 Years to 45 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Overweight or Obesity
- Interventions
- TERN-601, Matching Placebo
- Drug · Other
- Lead sponsor
- Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Homewood, Alabama • Tucson, Arizona + 14 more
- Conditions
- Obesity
- Interventions
- Not listed
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Postprandial Hypoglycemia
- Interventions
- Exendin-(9-39), Vehicle
- Drug · Other
- Lead sponsor
- Diva De Leon
- Other
- Eligibility
- 6 Months to 18 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- NAFLD, Diabetes, Obesity
- Interventions
- GLP-1 receptor agonist
- Drug
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Critically Ill, Hypoglycemia
- Interventions
- Glucagon-Like Peptide-1, Saline
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 21 Years to 75 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Diabetes Mellitus, Non-Insulin-Dependent
- Interventions
- NNC 90-1170
- Drug
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Sleep Apnea, Sleep Disordered Breathing
- Interventions
- liraglutide
- Drug
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Endometrioid Endometrial Adenocarcinoma
- Interventions
- Glucagon-like peptide 1 receptor agonist
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Obesity & Overweight, Diabetes (DM)
- Interventions
- Glucagon-Like Peptide-1 Agonist (GLP-1)
- Drug
- Lead sponsor
- Ohio State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Obesity
- Interventions
- Tirzepatide, Mibavademab, Tirzepatide-Placebo, Mibavademab-Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 392 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 17
- States / cities
- Gardena, California • Irvine, California • Los Angeles, California + 14 more
- Conditions
- Obesity, Overweight
- Interventions
- VRB-101, Placebo
- Drug
- Lead sponsor
- Verdiva Bio Dev Limited
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 22
- States / cities
- Anniston, Alabama • Cullman, Alabama • Phoenix, Arizona + 18 more
- Conditions
- Crohn Disease
- Interventions
- Tirzepatide, Mediterranean diet
- Drug · Behavioral
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Drug Discontinuation, Substance Use Disorders, Eating Behavior Changes, Tirzepatide
- Interventions
- Discontinuation and Reinitiation of Tirzepatide
- Other
- Lead sponsor
- The University of Texas at Dallas
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Type 2 Diabetes
- Interventions
- Tirzepatide, Insulin Lispro (U100)
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,428 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 40
- States / cities
- Sheffield, Alabama • Fresno, California • Huntington Park, California + 36 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Tirzepatide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 478 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 28
- States / cities
- Huntington Park, California • Los Angeles, California • Montclair, California + 24 more
- Conditions
- Type 2 Diabetes, Hypertriglyceridemia
- Interventions
- Saxagliptin
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2024
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Smoking Cessation, Weight, Body
- Interventions
- Liraglutide, Placebo, Smoking Cessation Counseling
- Drug · Behavioral
- Lead sponsor
- Rebecca Ashare
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Spinal Cord Injuries, Type 2 Diabetes
- Interventions
- Semaglutide Injectable Product, Placebo
- Drug · Other
- Lead sponsor
- Marzieh Salehi
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 2
- States / cities
- San Antonio, Texas